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Summary 
We investigated the effects of estrogens on the regulation of dopamine receptors in the MtT/Wl5 
transplantable rat pituitary tumor. Diethylstilbestrol (DES) and 17&estradiol treatment in female rats 
significantly decreased the number of dopamine binding sites (B,,,) from 85 k 3.9 fmol/mg protein in 
untreated rats to 9.2 k 1.2 and 8.2 + 2.8 fmol/mg protein in DES and 17/%estradiol-treated rats, respec- 
tively, while the binding affinities ( Kd) did not change significantly. Testosterone treatment did not change 
the B,,,, while ovariectomy resulted in a significant increase in the B,,, (146.3 + 6.7 fmol/mg protein). 
The effects of DES on the B,,, were reversible, since removal of the DES for one week before sacrificing 
the animals led to a marked increase in the B,,, (54.9 f 3.1 fmol/mg protein). 
Pituitaries from normal female rats treated with DES for 6 and 9 weeks had a significant decrease in the 
B max. 
These results show that the number of dopamine binding sites in the membranes of MtT/WlS tumors is 
decreased by estrogen treatment and that this effect is reversible after removal of the estrogenic stimulus. 
The MtT/WlS transplantable pituitary tumor 
which secretes PRL and GH was initiated by 
Furth et al. (1956) by diethylstilbestrol (DES) 
treatment in rats. Although this tumor was ini- 
tially dependent on estrogens for growth, it subse- 
quently became autonomous. Recently Cronin et 
al. (1982) reported that the MtT/WlS tumor had 
dopamine receptors, but that this tumor was re- 
fractory to dopaminergic inhibition of prolactin 
release. Earlier reports indicated that bromocrip- 
tine did not inhibit prolactin release from the 
MtT/WlS tumor (Lamberts and MacLeod, 1979). 
We have recently observed that the growth of 
the MtT/WlS tumor was inhibited by DES (Lloyd 
et al., 1985). This observation was surprising in 
light of the origin of this tumor. However, other 
recent reports have indicated that growth of the 
MtTF4 transplantable pituitary tumor was also 
inhibited by estrogen (Morel et al., 1982). The 
MtTF4 pituitary tumor has recently been reported 
to have dopamine receptors which are down-regu- 
lated by 17b-estradiol treatment (Andre et al., 
1982; Albaladejo et al., 1984). We previously noted 
that the DES inhibition of MtT/WlS tumor 
growth was associated with a relative increase in 
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the GH-producing cells and a decrease in the 
PRL-producing cells (Lloyd et al., 1985). Because 
of these findings we investigated the MtT/WlS 
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tumor for the presence of dopamine receptors and 
examined the regulation of these receptors by DES 
and several steroid hormones. The effects of DES 
on dopamine receptors in the MtT/WlS tumor 
were compared with the effects of DES on dopa- 
mine receptors in normal and in hyperplastic rat 
pituitary tissues after DES treatment. 
Materials and methods 
Animals 
Forty-day-old Wistar-Furth female rats (Harlan, 
Madison, WI) were inoculated with 2 mm pieces 
of minced MtT/WlS tumor subcutaneously (s.c.) 
over the right lower flank. This tumor was ob- 
tained from Dr. Bogden at the Mason Research 
Institute (Worcester, MA) and has been main- 
tained in our laboratory for 3 years with more 
than 20 passages. The tumors secrete large amounts 
of PRL and GH and contain immunoreactive PRL 
and GH in the cytoplasm (Lloyd et al., 1985). 
Animals were exposed to a cycle of 12 h light and 
12 h darkness. Food and water were available ad 
hbitum. Silastic tubes with 10 mg of DES, 17p- 
estradiol or testosterone were prepared as previ- 
ously described (Lloyd et al., 1985). Four weeks 
after tumor implantation 5 animals per group with 
palpable tumors were given 10 mg of DES. estro- 
gen, or testosterone in Silastic tubes. Control 
animals received empty Silastic tubes. After vari- 
ous periods of treatment, animals were sacrificed 
by decapitation between 9 and 11 a.m. In some 
experiments after 1 week of DES treatment the 
Silastic tubes were removed under light anesthesia 
and these 5 animals were followed for one week 
before sacrificing. Another group of 8 rats was 
ovariectomized one week after tumor implanta- 
tion. These animals were subsequently sacrificed 6 
weeks after ovariectomy. Tumor tissues were used 
for dopamine receptor studies and for immuno- 
histochemical studies. 
In other experiments groups of five 40-day-old 
Wistar-Furth female rats without tumors received 
10 mg of DES in Silastic tubes. After 3, 6 and 9 
weeks, the rats were sacrificed between 9 and 11 
a.m. and the pituitaries were used for dop,amine 
receptors and immunohistochemical studies. 
Dopumine receptor hiding studies 
The MtT/WlS tumors and pituitary tissues 
were rapidly excised after decapitation. Tumor 
cells and pituitary tissues were separated from 
adjacent areas of necrosis and hemorrhage. Sec- 
tions of the tumors were fixed in neutral buffered 
formalin and stained with hematoxylin and eosin 
to confirm that non-necrotic pituitary tissue was 
present. The tissues were placed into ice-cold buffer 
(15 mM Tris, 120 mM NaCI, 5 mM KCl, 1 mM 
MgCl,, 2 mM CaCl,, 0.1 mM EDTA, 0.1% 
ascorbate and 12.5 PM nialamide, pH 7.3) which 
was used throughout the receptor study. The tis- 
sues were minced with sterile scalpel blades, trans- 
ferred to fresh buffer (6 vols./wet weight) and 
homogenized with a Thomas Homogenizer 4 times 
for 60 s each time. The homogenate was filtered 
through 4 layers of cheesecloth then centrifuged at 
1000 X g for 10 min at 4°C. The supernatant was 
centrifuged at 70000 x g for 60 min and the pellet 
was resuspended in ice-cold buffer and homoge- 
nized for 20 s. This homogenate was divided into 
samples and stored frozen at - 80°C for 2 months 
or less with no apparent change in the dopamine 
receptor content. Aliquots were taken for protein 
determinations (8). The dopamine receptor assay 
was performed at 37°C using the procedure of 
Cronin et al. (1979, 1982) with [3H]spiperone 
([1-pheny/-4-3H]spiroperidol, spec. act. 22-26 
Ci/mmol, New England Nuclear, MA). The 
[3H]spiperone was diluted in 5% ethanol buffer. 
Bromocriptine (Sandoz, New Jersey), haloperidol, 
spiperone (Janssen Pharmaceutical, Beerse, Bel- 
gium) and Pergolide (Eli Lilly, Indianapolis, IN) 
were generous gifts. d- and I-Butaclamol were 
from Research Biochemicals (Wayland, MA) while 
dopamine, epinephrine and norepinephrine were 
from Sigma (St. Louis, MO). Duplicate samples 
were used. Protein concentrations ranged from 0.6 
to 0.9 mg/ml, and the total volume of the assay 
tube was 0.6 ml. After incubation at 37°C the 
samples had 3 ml of cold Tris buffer added. They 
were kept on ice 5-10 min before filtration and 
then washed 3 times with 3 ml of ice-cold buffer 
each time for 20-30 s. The radioactivity was 
trapped on Whatman GF/C filters and after dry- 
ing for 2 h at 60°C was measured by liquid 
scintillation counting in Scintiverse (Fisher, De- 
troit, MI) with a machine counting efficiency of 
30-40s. Specific binding was defined as the dif- 
ference between the radioactivity bound to the 
membranes in the absence (total binding) and in 
the presence of a lOOO-fold excess (2 PM) d- 
butaclamol (non-specific binding). The maximal 
number of binding sites (II,,,,) and the apparent 
dissociation constant ( K, ) were determined from 
Scatchard plots (Scatchard, 1949) which were fitted 
to the experimental data by least-squares regres- 
sion analysis. Statistical analysis was done with the 
Student t-test. 
Results 
Dopamine receptor binding capacity was detec- 
table in the MtT/WlS tumors from all untreated 
animals. Specific binding of [‘Hlspiperone in- 
creased linearly between 0.3 and 1.2 mg/assay 
tube. Specific binding to the membrane prepara- 
tion was reduced by more than 95% after prein- 
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Fig. 1. A Scatchard and direct (inset) plot of a saturation 
isotherm experiment. The K, in this experiment was 0.516 nM 
and maximal binding was 57 fmol/mg assay protein. Con- 
centrations of [3H]spiperone from 0.117 to 3.76 nM were 
studied. The regression line significantly approximated the 
experimental points ( r2 = 0.98). 
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min at 37”C, but not with 0.25% ribonuclease. 
Specific binding as a function of incubation tem- 
perature for 30 min was shown to decrease in this 
order: 37”C, 23’C, 4°C and 60°C. The optimal 
pH for specific binding was 7.2, while pH 2 re- 
duced specific binding to 20% of that seen at pH 
7.2. All binding assays were done at 37°C for 30 
min at pH 7.2. The protein concentration used in 
each assay was 0.6-0.9 mg/assay tube. With these 
conditions the specific binding represented from 
40 to 82% of total binding. Specific binding did 
not change within the maximum 2-month period 
of storage of the homogenate at - 80°C. A typical 
Scatchard plot is shown in Fig. 1. The equilibrium 
dissociation constant, K,, for 5 experiments was 
0.614 f 0.107 nM and the total number of binding 
sites was 87 + 3.9 fmol/mg assay protein for 
plasma membranes from the MtT/WlS tumor. 
The character of the binding was determined by 
competition experiments (Table 1). The MtT/WlS 
tumor binding sites were stereoselective with 
preferential binding of the d-butaclamol isomer. 
The rank order of potency of various ligands at 
these sites was similar to the protency profile of 
dopamine receptors previously characterized in the 
anterior pituitary gland and in MtT/WlS tumors 
(Table 1). 
The results of various treatments on the B,,,,, of 
the MtT/WlS tumor are summarized in Fig. 2. 
Ovariectomy caused an increase in the B,,,,,, while 
treatment with DES and 17P-estradiol for one 
week produced a significant decrease. After one 
week of DES treatment the MtT/WlS tumors 
weighed 1.2 f 0.6 g, while tumors from control 
animals weighed 2.5 f 1.3 g. Three weeks of DES 
treatment resulted in MtT/WlS tumors weighing 
0.74 f 0.2 g, while tumors from control animals 
weighed 27.8 + 9 g (mean + SEM for 4 determina- 
tions). The pituitaries of control rats and rats 
treated with DES for 1 and 3 weeks weighed 
7.6 +0.6 mg, 10.7 f0.4 mg, and 23.6 + 1.0 mg 
respectively (mean f SEM for 4 determinations). 
Treatment with testosterone did not change the 
B,,,,,. Preliminary experiments showed that after 2 
and 3 weeks of DES treatment dopamine receptor 
binding was not measurable in the tumors. The 
dopamine receptor affinities after various treat- 
ments were unchanged. The K,s for tumors from 
untreated controls, ovariectomized groups, testos- 
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TABLE 1 
COMPETITION BY VARIOUS AGENTS FOR [3H]SPIPERONE BINDING TO THE MtT/WlS TRANSPLANTABLE PITUI- 
TARY TUMOR 
The apparent K, was determined in independent experiments with at least 3 competitor concentrations. The apparent K, f standard 
error of the mean was calculated according to the equation K, = IC5,, (1 +C/K,) where the ICs,, is the concentration of the drug 
which competes for 50% of the specific binding defined by 2 PM d-butaclamol. C is the concentration of [‘Hlspiperone (0.117-0.94 
nM). K, was determined from saturation isotherm studies (0.61 nM). Specific binding was 50-70s of total binding. 
Agonist K, (nM) n Antagonist K, (nM) n 
Bromocriptine 49.8* 29 3 Spiperone 0.84 k 6.46 4 
Pergolide 2271 ? 409 5 ( + )Butaclamol 2.45 k 1.4 3 
Dopamine 60480 ?I1945 3 Haloperidol 54.8 ? 14 3 
Epinephrine 194888 k65625 3 Chloropromazine 114 & 16 3 
Norepinephrine 51829 2 (-)Butaclamol 9 394 +2528 5 
terone-, DES- and estradiol-treated groups were 
0.61 k 0.13, 0.58 + 0.12, 0.67 + 0.12, 0.69 k 0.13 
and 0.94 f 0.49 respectively. 
To evaluate the reversibility of the down-regu- 
lation of dopamine receptors by DES, a group of 5 
rats was treated with DES for one week. The DES 
was removed for one week before the animals were 
sacrificed and dopamine receptor levels measured. 
The B,,,, was 54.9 k 3 fmol/mg protein, while the 
K, was 0.90 f. 0.26, incidating that the dopamine 
receptor levels increased after removal of DES 
without any significant changes in the affinity for 
the receptor. 
CON OVEX TEST El76 DES 
Of2 
Fig. 2. The effects of various treatments on the MtT/WlS 
dopaminergic binding capacity. Each value for binding capacity 
is the mean+ SEM. Concentrations of [‘Hlspiperone from 0.117 
to 1.88 nM were used. The number of binding experiments is 
shown in parentheses. Significant differences included * P < 
0.05. ** P < 0.01 and *** Pi 0.001. CON, control; OVEX, 
ovariectomy; TEST. testosterone; E17B, 17fi-estradiol; DES, 
diethylstilbestrol; DES DC, diethylstilbestrol discontinued for 
1 week before sacrificing rats. 
When the effects of estrogen on the non-tumor- 
ous pituitary were evaluated after DES treatment 
for zero, 3, 6 and 9 weeks, there was a significant 
decrease in dopamine receptor levels after 6 and 9 
weeks of DES treatment (Fig. 3). Although the 
B ,,,r,li was greater than that seen with the MtT/WlS 
tumors, the K, was in the same range with values 
of 0.84 + 0.19, 0.95 + 0.25, 0.52 + 0.28 and 0.83 + 
0.23 in normal pituitaries and pituitary tissues 
after 3, 6 and 9 weeks of DES treatment respec- 
tively. 
CON DES DES DES 
3wk 6wk 9wk 
Fig. 3. The effects of various periods of DES treatment on the 
anterior pituitary gland dopaminergic binding capacity. Con- 
centrations of [‘Hlspiperone from 0.117 to 1.88 nM were used. 
Each value for binding capacity is the mean * SEM. The num- 
ber of binding experiments is shown in parentheses. Significant 
differences included * P < 0.05, ** P < 0.01 and *** P < 0.001. 
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Discussion 
This study examines the effects of estrogen 
treatment on dopamine binding of [3H]spiperone 
to dopamine receptors of MtT/WlS tumor cell 
membranes. DES and estrogen treatment resulted 
in a decrease of the maxima1 number of binding 
sites while the affinity for the receptor was not 
modified. This effect was not seen with testos- 
terone, which suggests that there is hormone 
specificity. The effects of estrogens on the dopa- 
mine receptor of MtT/WlS tumors is analogous 
to the effects of estradiol on the MtTF4 tumor 
dopamine receptor levels (Albaladejo et al., 1984). 
However, the present study adds several new ob- 
servations about the regulation of dopamine recep- 
tor levels in the MtT/WlS tumor. The first is that 
ovariectomy increases the B,,;,, of the tumor mem- 
brane. We have previously shown that the 
MtT/Wl5 tumor grows at a slower rate after 
ovariectomy, indicating that a certain level of 
estrogen is still needed for optima1 growth of this 
tumor (Lloyd et al., 1985). Heiman and Ben- 
Jonathan (1982) noted that the B,,,,, in pituitaries 
from ovariectomized rats was high and subse- 
quently decreased after estradiol treatment. The 
second new observation in the present study is 
that discontinuation of the DES after one week 
resulted in increased levels of dopamine receptors. 
Silastic tubes with 10 mg of DES have been esti- 
mated to release approximately 45 pg/day of this 
estrogen (Wiklund et al., 1981) thus the animals 
are receiving a pharmacologic dose of estrogens. 
Not surprisingly dopamine receptors were not de- 
tected after 2 and 3 weeks of DES treatment. The 
subsequent rebound effect after removal of the 
DES suggests that the presence of dopamine re- 
ceptors and inhibition of tumor growth by DES 
may be related in some way, since the tumor 
resumed growth when the DES was discontinued 
(Lloyd et al., 1985). Alternatively, this relationship 
may be merely coincidental, since DES treatment 
in normal pituitary glands resulted in a decrease in 
dopamine receptors after 6 and 9 weeks in spite of 
continued proliferation of the pituitary cells 
(Lloyd, 1983). Although the K, and K, values 
were higher than some reported values in the 
literature (Cronin et al., 1980) these values are 
lower than other reported K, and K, values for 
[3H]spiperone binding to plasma membranes of 
pituitary tumors induced by estrone treatment 
(Eljarmax et al., 1985). 
The MtT/WlS tumor has at least 2 cell popula- 
tions, one producing GH and the other PRL al- 
though some of the cells may produce both PRL 
and GH (Parsons et al., 1978, 1980). Our recent 
experiments have shown that there is a shift in the 
population of GH and PRL cells after DES treat- 
ment with an increase in the GH-producing cells 
(Lloyd et al., 1985). This latter observation may 
possibly explain the decrease in dopamine recep- 
tors if a population of GH cells without dopamine 
receptors constitutes most of the cell population in 
DES-treated rats. The alternate hypothesis that 
DES treatment resulted in a decrease in the num- 
ber of dopamine receptors per cell in the tumor 
cannot be excluded. The results seen in DES- 
treated normal pituitaries would support this latter 
view, because we and others have shown previ- 
ously that there is an increase in the number of 
PRL cells after estrogen treatment in the normal 
pituitary gland (Lieberman et al., 1978; Lloyd, 
1983). The observation that ovariectomy results in 
increased dopamine receptor density and a slower 
rate of tumor growth while DES decreases dopa- 
mine receptor density but also slows tumor growth 
is somewhat paradoxical and might suggest that 
DES may have only partial agonist activity com- 
pared to 17P-estradiol. However most of the avail- 
able evidence from in vitro studies of 17P-estra- 
dioland DES on the synthesis of prolactin by 
primary cultures of dispersed anterior pituitary 
cells indicates that DES is a complete agonist of 
17/?-estradiol (Jordan and Lieberman, 1984). 
The effects of chronic estrogen treatment on 
dopamine receptor levels have been quite variable 
(Andre et al., 1982; Bression et al., 1983; Di Paolo 
and Falardeau, 1984). Andre et al. (1982) did not 
find a significant decrease in the B,,,,, in pituitary 
dopamine receptors after 90 days of estradiol 
treatment. Di Paolo and Falardeau (1984) found 
that after 25 weeks of estrogen treatment the B,,,.,, 
was not significantly decreased in estradiol-in- 
duced pituitary tumors, although bromocriptine 
did produce a decrease in the B,,,,,. Other workers 
(Bression et al., 1983) have found a significant 
decrease in the B,,,;,, with chronic estrogen treat- 
ment which agrees with our present report. The 
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dopamine receptor has recently been identified in 
an estrone-produced pituitary tumor, although it is 
not known if the receptor levels were decreased 
compared to those in normal pituitaries (Eljarmax 
et al., 1985). If one considers that the number of 
PRL cells increases by more than 2-fold in estro- 
gen-induced pituitary tumors (Lloyd, 1983) then 
even if the number of dopamine receptors for 
estrogen-treated pituitaries remained constant, 
there would be a significant decrease in dopamine 
receptors if the receptors were expressed per mam- 
motroph surface area (Cronin, 1982). 
Previous studies have not found that DES or 
17/I-estradiol interfere with spiperone binding (Al- 
baladejo et al., 1984). Although estrogen may be 
metabolized to catechol estrogens and thus inter- 
act with the dopamine receptor, the affinity of 
catechol estrogens for the dopamine receptor is 
low (K, = 0.2 PM) (Schaeffer and Hsueh, 1979) 
and the procedure used for membrane preparation 
should be efficient in washing them out. Other 
investigators have shown that catechol estrogens 
do not interact at the same binding site as 
(‘Hlspiperone (Cronin and Weiner, 1979). 
The dopamine receptors present in the 
MtT/Wl5 tumors are indistinguishable from the 
dopamine receptors in normal anterior pituitary 
glands (Cronin et al., 1982). Nevertheless, the 
dopamine receptors in these tumors are considered 
to be functionless since the tumors are refractory 
to the dopaminergic inhibition of prolactin release 
(Lamberts and MacLeod, 1979). An analogous 
condition has also been reported with the 7315a 
tumor which produces PRL and ACTH (Cronin et 
al., 1981). The MtT/WlS and 7315a tumors are 
unlike other PRL-producing pituitary tumors, such 
as the GH, cell line which does not have high-af- 
finity dopamine receptors (Cronin et al., 1980). 
The finding of functionless receptors in the 
MtT/WlS and 7315a PRL-secreting tumors corre- 
lates well with the previous findings that 
brom~riptine did not cause tumor regression or 
suppress elevated serum PRL levels in rats with 
these tumors (Lamberts and MacLeod, 1979). 
Recent evidence suggests that the high-affinity 
agonist binding state of the 02 receptor in mediat- 
ing the decrease in prolactin secretion occurs via 
attenuation of adenylate cyclase and is dependent 
on nucleotides (McDonald et al., 1984). The 
MtT/WlS dopamine receptor has been found to 
be sensitive to guanine nucleotides suggesting that 
a G/F-like protein interacts with the dopamine 
receptor as it does in the normal anterior pituitary 
gland and that the functional defect in the 
MtT/WlS tumor probably does not occur at the 
cell membrane (Ross and Gilmore, 1980). How- 
ever, it remains to be determined where the func- 
tional lesion in the MtT/WIS plasma membrane 
dopamine receptor is located. 
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